$2.06
2.83% yesterday
Nasdaq, Jun 11, 10:00 pm CET
ISIN
US4277461020
Symbol
HRTX
Sector
Industry

Heron Therapeutics Inc Stock price

$2.06
+0.01 0.49% 1M
+0.37 21.89% 6M
+0.53 34.64% YTD
-1.58 43.41% 1Y
-16.17 88.70% 5Y
-26.04 92.67% 10Y
-125.94 98.39% 20Y
Nasdaq, Closing price Wed, Jun 11 2025
-0.06 2.83%
ISIN
US4277461020
Symbol
HRTX
Sector
Industry

Key metrics

Market capitalization $314.28m
Enterprise Value $413.35m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 2.78
P/S ratio (TTM) P/S ratio 2.12
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth 12.44%
Revenue (TTM) Revenue $148.52m
EBIT (operating result TTM) EBIT $-2.88m
Free Cash Flow (TTM) Free Cash Flow $-23.70m
Cash position $50.68m
EPS (TTM) EPS $-0.06
P/E forward negative
P/S forward 1.98
EV/Sales forward 2.61
Short interest 29.33%
Show more

Is Heron Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,842 stocks worldwide.

Heron Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

4 Analysts have issued a Heron Therapeutics Inc forecast:

4x Buy
100%

Analyst Opinions

4 Analysts have issued a Heron Therapeutics Inc forecast:

Buy
100%

Financial data from Heron Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
149 149
12% 12%
100%
- Direct Costs 39 39
32% 32%
26%
110 110
46% 46%
74%
- Selling and Administrative Expenses 99 99
11% 11%
67%
- Research and Development Expense 14 14
69% 69%
10%
-0.52 -0.52
99% 99%
0%
- Depreciation and Amortization 2.35 2.35
18% 18%
2%
EBIT (Operating Income) EBIT -2.88 -2.88
97% 97%
-2%
Net Profit -7.79 -7.79
90% 90%
-5%

In millions USD.

Don't miss a Thing! We will send you all news about Heron Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Heron Therapeutics Inc Stock News

Positive
Seeking Alpha
about one month ago
HRTX's Q1'25 earnings highlight Cinvanti as the top earner, but Zynrelef shows strong growth potential, with 60% growth in net sales vs Q1'24. HRTX reported net income of $2.6M and raised its full-year adjusted EBITDA guidance, but potential equity offerings to manage debt remain a risk. HRTX's CEO speaks of Zynrelef's multi-hundred-million-dollar potential, although it may take several more qu...
Neutral
Seeking Alpha
about one month ago
Heron Therapeutics, Inc. (NASDAQ:HRTX ) Q1 2025 Earnings Conference Call May 6, 2025 8:00 AM ET Company Participants Melissa Jarel - Executive Director, Legal Craig Collard - Chief Executive Officer Ira Duarte - Executive Vice President, Chief Financial Officer Conference Call Participants Yuxi Dong - Jefferies Serge Belanger - Needham & Company Carl Byrnes - Northland Capital Markets Operator ...
Neutral
PRNewsWire
about one month ago
Generated Q1 2025 Net Revenue of $38.9 million Delivered record Q1 2025 Adjusted EBITDA of $6.2 million Reached settlement with Mylan Pharmaceuticals, Inc., regarding the parties' CINVANTI ® and APONVIE ® patent litigations, including an agreed market entry date of June 1, 2032 Adjusted EBITDA guidance raised to a range of $4 - $12M for full year 2025 CARY, N.C. , May 6, 2025 /PRNewswire/ -- He...
More Heron Therapeutics Inc News

Company Profile

Heron Therapeutics, Inc. is a biotechnology company, which engages in the development of pharmaceutical products for patients suffering from cancer. Its products portfolio include SUSTOL, Cinvanti, HTX-011, and HTX-034. The company was founded in February 1983 and is headquartered in Redwood City, CA.

Head office United States
CEO Craig Collard
Employees 122
Founded 1983
Website www.herontx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today